Hepion Pharmaceuticals Stock Revenue
| HEPA Stock | USD 0.78 0.26 25.00% |
Hepion Pharmaceuticals fundamentals help investors to digest information that contributes to Hepion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hepion Stock. The fundamental analysis module provides a way to measure Hepion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hepion Pharmaceuticals stock.
| Last Reported | Projected for Next Year |
Hepion | Revenue |
Hepion Pharmaceuticals Company Revenue Analysis
Hepion Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Hepion
Projected quarterly revenue analysis of Hepion Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Hepion Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Hepion Pharmaceuticals' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Hepion Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Hepion Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Hepion Pharmaceuticals is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 0.0. Hepion Pharmaceuticals adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.Hepion Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Hepion Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Hepion Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Hepion Pharmaceuticals' value.| Shares | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 175 | Sbi Securities Co Ltd | 2024-12-31 | 125 | Advisor Group Holdings, Inc. | 2024-12-31 | 113 | Group One Trading, Lp | 2024-12-31 | 84.0 | Bank Of America Corp | 2024-12-31 | 57.0 | Barclays Plc | 2024-12-31 | 16.0 | Hanson Mcclain Inc | 2024-12-31 | 2.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Advisornet Financial, Inc | 2024-12-31 | 0.0 | Anson Funds Management Lp | 2024-12-31 | 231.8 K | Blackrock Inc | 2024-12-31 | 83 K |
Hepion Fundamentals
| Return On Equity | -2.88 | ||||
| Return On Asset | -1.1 | ||||
| Current Valuation | 3.15 M | ||||
| Shares Outstanding | 34.65 M | ||||
| Shares Owned By Insiders | 3.07 % | ||||
| Shares Owned By Institutions | 2.31 % | ||||
| Number Of Shares Shorted | 4.75 M | ||||
| Price To Earning | (3.01) X | ||||
| Price To Book | 2.11 X | ||||
| EBITDA | (49.26 M) | ||||
| Net Income | (48.93 M) | ||||
| Cash And Equivalents | 59.15 M | ||||
| Cash Per Share | 0.78 X | ||||
| Total Debt | 209.02 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.77 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (40.89 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (4.40) X | ||||
| Target Price | 30.0 | ||||
| Number Of Employees | 22 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 720.73 K | ||||
| Total Asset | 18.09 M | ||||
| Retained Earnings | (224.63 M) | ||||
| Working Capital | 12.2 M | ||||
| Current Asset | 4.82 M | ||||
| Current Liabilities | 1.81 M | ||||
| Net Asset | 18.09 M |
About Hepion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hepion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hepion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hepion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:Check out Hepion Pharmaceuticals Piotroski F Score and Hepion Pharmaceuticals Altman Z Score analysis. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.